# A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients

> **NCT03053427** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 375 (actual)

## Conditions studied

- Restless Legs Syndrome (RLS)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Gabapentin enacarbil

## Key facts

- **NCT ID:** NCT03053427
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-30
- **Primary completion:** 2018-06-25
- **Final completion:** 2018-06-25
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053427, "A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03053427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*